The application of genomic and molecular data in the treatment of chronic cancer pain

被引：24

作者：

Turabi, Ali ^{[1
]}

Plunkett, Anthony R. ^{[1
]}

机构：

[1] Walter Reed Army Med Ctr, Def & Vet Pain Management Initiat, Anesthesia & Operat Serv, Washington, DC 20307 USA

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2012年 / 105卷 / 05期

关键词：

cancer pain; translational medicine; gene therapy; METHYLTRANSFERASE COMT GENE; NECROSIS-FACTOR-ALPHA; SUBSTANCE P-SAPORIN; DOUBLE-BLIND; INTRATHECAL ZICONOTIDE; NEUROPATHIC PAIN; DORSAL-HORN; OSTEOPROTEGERIN LIGAND; MORPHINE REQUIREMENTS; HEAT HYPERALGESIA;

D O I：

10.1002/jso.21707

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Many cancer patients will develop complex pain syndromes requiring aggressive, innovative, and comprehensive multimodal pain management strategies. Recently, data from both animal studies and clinical trials have allowed clinical research to focus on creating applicable clinical treatment strategies. This article is a review of genomic and molecular data, which has contributed to creating novel modalities for use in clinical pain management of patients with cancer-induced pain. J. Surg. Oncol. 2012; 105:494501. (c) 2012 Wiley Periodicals, Inc.

引用

页码：494 / 501

页数：8

共 101 条

[1]

Allen JW, 2006, TOXICOL SCI, V91, P286, DOI 10.1093/toxsci/kfj143

[2]

[Anonymous], 2003, JOINT COMM IMPR QUAL

[3] Reduction and prevention of vincristine-induced neuropathic pain symptoms by the non-benzodiazepine anxiolytic etifoxine are mediated by 3α-reduced neurosteroids [J].